Source Group LLC’s Post

Register using the link below to join our webcast tonight at 9:00pm EST / 6:00pm PST to hear more about the progress shared today on DISC-0974 at #ASH24 and plans for next steps in development #Anemia in #Myelofibrosis. #DiscMedicine

At #ASH24, Jeremy DiGennaro, DO discussed high-risk myelodysplastic syndrome treated with a hypomethylation agent and venetoclax. The retroactive study focused anti-fungal prophylaxis, incidence of fungal infections, time to absolute neutrophil count recovery and impact on overall survival. Read more: https://lnkd.in/eSBHnPGY American Society of Hematology #MoffittASH24

How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

Mark your calendars for a live webinar hosted by Fortis Institute of Blood Disorder on Innovations in Hematology. Join us on May 17th, 2024, from 7 PM to 8 PM and gain invaluable knowledge from leading specialists Dr. Jayastu Senapati and Dr. Nikhil M Kumar. Discover new technologies and innovative practices that are shaping the future of hematology. #AtFortisWeCare #FortisHealthcare #Webinar

At #ASH24, Hammad Tashkandi, MD discussed the clinical relevance in classification methods and the prognostic implications of subgrouping within TP53-mutated myelodysplastic neoplasms as outlined by WHO and ICC. Read more: https://lnkd.in/e_SzcJXH American Society of Hematology #MoffittASH24

🔬Amzing Notes About Hematology Review♥️ ✔️Do Share It. 🤔What You Will Learn: 📌Literally Everything About Hematology(From Blood Collection to the Each indices Significance) #knowledgesharing #Laboratoryprofessional #BiomedicalEngineers

The American Journal of Hematology recently published the results of a phase II study of BTK inhibitor orelabrutinib in patients with ITP.  “The phase 2 study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP. Further investigation through larger, randomized, placebo-controlled trials is warranted to definitively confirm these findings and establish orelabrutinib as a valuable treatment option for ITP management，” said Professor Ming Hou, the leading PI. Read more: https://lnkd.in/eXSyjcVD Full paper is here: https://lnkd.in/evmzBApi

Unlock the secrets of hematology staining techniques with our latest blog post on the Wright-Giemsa stain! Perfect for laboratory professionals and students, this guide provides step-by-step instructions to help you achieve precise and accurate results 🔬🎨 Dive into the details here: https://bit.ly/3ycvOvL #WrightGiemsa #LabTutorial #HardyDiagnostics

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj